Molika Ashford
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.

Articles Authored by Molika Ashford
Investigators highlighted data from efforts in breast and bladder cancer, demonstrating that the company's platform could help oncologists better personalize treatment.
ChromaCode Lung Cancer Assay Shows Advantages in New Data at AMP as Company Eyes Next Applications
Premium
The firm is working with early adopters of its NSCLC kit as it develops new tests for cancer minimal residual disease monitoring and kidney transplant rejection.
As Clinical MRD Tests Boom, Natera Expands Efforts to Build Evidence for New Cancer Indications
Premium
Significant volume growth for its Signatera minimal residual disease test helped boost the company's Q3 revenues.
The company has shifted its strategy to allow for multi-platform IVD adaptations of its current lab-developed tests, aiming to reach a broader diagnostics market.
Guardant Health Q3 Revenues Rise 22 Percent as Oncology Test Volume Continues to Grow
The company is celebrating recent milestones for its MRD testing arm and its anticipated expansion into colorectal cancer screening.
The company's data, presented at a recent meeting and simultaneously published, showed performance results analogous to currently marketed tests.
The company reported that its Barrett's esophagus risk assay saw volumes more than triple in Q3 2023 compared to the same period last year.
The company recently shared positive results from its Blue-C study, intended to support an FDA approval bid for a second generation of its colon cancer screening test.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.
In New TRACERx Data, Personalis MRD Test Shows Improved Sensitivity With Potential Clinical Impact
Premium
The data, some of the first available for the firm's NeXT Personal test, indicated that its higher analytical sensitivity could lead to better risk prediction than competing tests.